Form 8-K Vaxcyte, Inc. For: Nov 05
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
Leerink Partners Reiterates Outperform Rating on Vaxcyte (PCVX)
November 6, 2024 5:59 AM ESTLeerink Partners analyst David Risinger reiterated an Outperform rating and $135.00 price target on Vaxcyte (NASDAQ: PCVX).
The analyst comments "Bottom Line: PCVX reported OpEx of $140M which was +2% or +$3M vs. our est. of $137M. The companys pipeline remains on track; the next readout to watch is VAX-24 Ph2 infant data at the end of 1Q25. We remain bullish on PCVX following competitive PCV pipeline commentary from PFE (MP) and GSK (Not Rated). PFE disclosed on its on... More
